KZIAKazia Therapeutics Ltd ADR
The Read
KZIA’s earnings releases have triggered large moves, with a roughly 20% rally after Q1 2026 results met EPS estimates despite a brief pullback, but a 12% drop followed the June 30 half-year update due to investor concerns over R&D funding and Paxalisib timelines.
The schedule
- Thu15Oct
Expected equity financing or strategic capital raise to extend the company's operating runway.
- Tue1Dec
Anticipated FDA/EMA feedback on the pivotal development and potential accelerated approval pathway for Paxalisib in Glioblastoma.
- Wed30Dec
Additional follow-up data from Paxalisib clinical trials presented at a mid-season oncology conference.
- Sun14Feb
Q4 2026 earnings release and initial clinical and strategic pipeline guidance for 2027.
Past
- Sun20Sep
Presentation of updated Paxalisib and EVT801 clinical data at a major late-2026 oncology meeting.
- Tue30Jun
Actual outcome: Bear · $12.41 at outcome
Kazia reported half-year EPS of -$3.95, which was exactly in line with consensus estimates. However, the stock fell 11.9% as the R&D funding update and cash runway projections failed to reassure investors, raising concerns over potential timeline slippage for Paxalisib and an accelerated need for external capital.
Around the FY26 half-year period ending 2026-06-30, Kazia will update investors on cash runway, R&D spend, and trial progress. If management demonstrates disciplined operating cash burn, confirms a multi-year runway, and outlines clear milestones for Paxalisib and the broader pipeline, the shares could grind up from $11.10 toward $13.00. A negative surprise on cost trajectory, timeline slippage, or an accelerated need for external capital could push the stock down toward $13.00.
- Mon29Jun
Actual outcome: Bull · $13.29 at outcome
KZIA reported Q1 2026 earnings with an EPS of -$3.95, exactly meeting analyst estimates. Despite a 7.4% pullback following the in-line results, the stock retained enough underlying strength to close at $13.39, successfully holding well above the $11.66 bull target.
KZIA reported Q1 2026 earnings with an EPS of -$3.95, exactly meeting analyst estimates. Despite a 7.4% pullback following the in-line results, the stock retained enough underlying strength to close at $13.39, successfully holding well above the $11.66 bull target.